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821-3 Evaluation of Beta-Blocker Dose in Community-Based 
Treatment of Heart Failure
Michael B. Fowler, Sandra R. Lottes, Jeanenne J. Nelson, Mary Ann Lukas, Edward M. 
Gilbert, Barry Greenberg, Barry M. Massie, William T. Abraham, Joseph A. Franciosa, 
and the COHERE Participant Physicians, GlaxoSmithKline Pharmaceuticals, 
Philadelphia, PA
Background: Randomized clinical trials (RCT) are performed in a very different environ-
ment from community practice. Heart failure patients in the community tend to be older,
have more comorbidities and are not cared for by the teams of heart failure specialists
who recruit patients into RCT, which may be especially important when beta-adrenergic
blocking drugs are prescribed to patients with heart failure.
Methods: In order to explore these prescribing effects we determined the dose of
carvedilol at end-titration in 4,113 patients in the practice setting and related this to physi-
cian type (cardiologists vs. non-cardiologists), heart failure severity, and the risks of hos-
pitalization and death.
Results: Dose achieved was not related to patients’ age, sex, race, history of diabetes or
other major demographic/clinical factors. The table shows factors that are influenced by
dose. 
Conclusions: Carvedilol dose in the community appears lower than in RCT, is influenced 
by NYHA functional class and tends to be higher when prescribed by cardiologists. At all 
doses, patients taking carvedilol have a lower incidence of death and heart failure hospi-
talization than those not receiving drug. This study demonstrates the utility of beta-
blocker therapy in the community and also confirms the RCT findings that lower doses of 
carvedilol can also provide clinical benefit in the usual care setting.
2:45 p.m.
821-4 Beta-Blockers Reduce Heart Failure Mortality 
Regardless of the Initial Heart Rate: Data From the 
ICONS Study
Jonathan G. Howlett, David E. Johnstone, Jafna L. Cox, Queen Elizabeth II Health 
Sciences Centre, Halifax, NS, Canada
Background: The role of heart rate reduction as a mechanism of beta blockade (BB)
effect in reduction of heart failure (HF) mortality is unknown. We sought to determine
whether the mortality effect of BB was related to initial heart rate in hospitalized HF
patients.
Methods: We utilized a prospective registry-based disease management database, the
Improving Cardiovascular Outcomes in Nova Scotia (ICONS) study, to identify individuals
with a discharge diagnosis of HF from any Nova Scotia hospital between October 15,
1997 and July 1, 2000. Patients were stratified according to their admission heart rate
quintiles in beats/min, (> 115, 100-115, 86-99, 72-85,<72). Variables were recorded pro-
spectively and censored at 2 years.
Results: There were 4888 unique patients, with average age of 76 years; 52% were
female. Patients prescribed BB were younger (age 74 vs. 77), with lower creatinine (133
vs. 143 umol/L) and higher EF (43% vs. 38%). After adjustment for co-morbid conditions,
hazard ratios for mortality with BB at two years were determined: 
Beta blocker prescription at discharge was associated with 37% lower two year mortality
(31% vs. 42%). This finding was consistent regardless of heart rate quintile. The hazard
ratio for BB in those with heart rate <65 bpm was 0.71, p= 0.09.
Conclusion: Beta blockers reduce mortality in unselected patients discharged from hos-
pital with HF regardless of their admission heart rate. Further data is required in those
with severe bradycardia.
3:00 p.m.
821-5 Risks of Death and Hospitalization in Heart Failure 
Patients Receiving Carvedilol Versus Metoprolol 
Tartrate: A Retrospective Claims-Based Study
Thomas E. Delea, Richard H. Stanford, May Hagiwara, John S. Edelsberg, Gerry Oster, 
Policy Analysis Inc., Brookline, MA, GlaxoSmithKline, Research Triangle Park, NC
Background: The Carvedilol or Metoprolol European Trial (COMET) demonstrated
improved survival with carvedilol (C) versus metoprolol tartrate (MT) in patients with
heart failure. The benefits of C versus MT in heart failure patients in typical US clinical
practice are unknown.
Methods: Using a large US health-insurance claims database linked to mortality informa-
tion from the US Social Security Administration, we compared the risks of death and hos-
pitalization and the costs of inpatient care in heart failure patients receiving C versus MT.
Subjects included all persons with >1 prescription for either C or MT (but not both) from
9/97-8/00 who, within 12 months of their first prescription for C or MT, had: (1) >1 medical
encounter with a primary diagnosis of heart failure; (2) >1 prescription for a loop diuretic;
(3) >1 prescription for an angiotensin-converting enzyme inhibitor; (4) no prescriptions for
a beta-blocker; and (5) continuous eligibility for health benefits.
Results: A total of 887 C patients and (coincidentally) an equal number of MT patients
met all criteria for inclusion in the study. Mean follow-up was 11 months (maximum, 36
months). Mean dose prescribed (mg/day supplied) was 24 for C and 70 for MT; mean
dose received (mg/day of follow-up) was only 14 for C and 44 for MT. C patients were
younger, more likely to be men, seen by a cardiologist, and prescribed digoxin; they also
had higher pretreatment heart failure costs. However, they were less likely to have hyper-
tension or other cardiovascular disease, and also had lower pretreatment cardiovascular
costs. Controlling for these differences using Cox proportional hazards regression,
receipt of C versus MT was associated with reduced risk of all-cause mortality (hazard
ratio .78; 95% CI .61-.99) and all-cause hospitalization (hazard ratio .76; 95% CI .66-.89).
In a propensity-matched sample of C and MT patients (n=562 each), expected costs of
cardiovascular inpatient care at 36 months were $6,164 lower for C than MT (95% CI
$1,330-$10,714).
Conclusion: Consistent with findings from COMET, our results suggest that C improves
survival and reduces costs of care compared with MT in heart failure patients in typical
US clinical practice.
3:15 p.m.
821-6 Beta-Blocker Utilization in Patients With Heart Failure: A 
Single-Center, Two-Year Follow-Up
Anoop Parameswaran, W. H. Wilson Tang, Gary S. Francis, Ritesh Gupta, James B. 
Young, Cleveland Clinic Foundation, Cleveland, OH
Background: The longitudinal pattern of beta-blocker (BB) utilization in a heart failure
(HF) practice setting has not been explored. Studies have not addressed the use of BB
over time to determine the “target” rates of use and reasons for discontinuation.
Methods: We reviewed consecutive patients with a clinical diagnosis of HF seen in a
specialized HF clinic between 3/01-5/01, and determined the pattern of BB utilization and
clinical outcomes over a subsequent 2-year period.
Results: From a cohort of 496 patients (mean age 61±14 years, 60% male, 53% with
ischemic etiology, mean LVEF 28±15%), 75% had a trial with a BB. On follow-up at 6, 12,
and 24 months, BB utilization rates were maintained at 69%, 70% and 67%, respectively.
Of the 120 non-BB users, 28 (23%) were subsequently initiated on BB, despite known
relative contraindications in 53% of patients. In 2 years, the discontinuation rate was
10%, and the most common reason for discontinuation was failure to restart BB following
hospitalization (31%). In this non-randomized cohort, the 2-year all-cause mortality was
comparable among different BBs (Figure).
Conclusion: Utilization rates of BB in our HF clinic remain constant (67-70%) throughout
a 2-year follow-up and likely represents a reasonable “target”. Of those who discontinued
Patient Characteristics 
and Outcomes
Carvedilol dose at end-titration (mg bid)
0 mg 3.125 mg 6.25 mg 12.5 mg 25 mg 50 mg
No. Patients 386 416 722 759 1672 158
Dose distribution in NYHA 
I patients (n=445)
7% 7% 17% 17% 46% 5%
Dose distribution in NYHA 
II patients (n=2099)
9% 9% 16% 18% 43% 4%
Dose distribution in NYHA 
III patients (n=1390)
11% 11% 18% 19% 38% 3%
Dose distribution in NYHA 
IV patients (n=131)
5% 18% 30% 21% 23% 4%
Dose distribution in 
cardiologists’ patients 
(n=2994)
10% 8% 14% 17% 47% 4%
Dose distribution in non-
cardiologists’ patients 
(n=1119)
7% 17% 27% 21% 24% 4%
HF hospitalizations per 
dose group
22% 17% 14% 11% 9% 8%
Odds ratio of HF 
hospitalizations (95% CI)
ref 0.71
(0.48-
1.06)p=0.097
4
0.59
(0.42-
0.85)p=0.0043
0.47
(0.33-
0.68)p<0.0001
0.44
(0.32-
0.62)p<0.0001
0.42
(0.21-
0.84)p=0.0137
KM rate per dose group 17% 11% 10% 7% 5% 5%
Hazard ratio for death 
(95% CI)
ref 0.66
(0.42-
1.05)p=0.078
0
0.55
(0.36-
0.84)p=0.0060
0.35
(0.22-
0.54)p<0.0001
0.25
(0.18-
0.39)p<0.0001
0.38
(0.16-0.93)p=0.034
ref = referent group for Odds Ratio and Hazard Ratio is the 0 mg dose group
KM rate = Kaplan-Meier rate for all-cause mortality
Initial Heart Rate (beats/min) Hazard Ratio 95% CI p Value
> 115 (n=990) 0.54 0.42- 0.71 0.0001
100-115 (n=1006) 0.62 0.47- 0.80 0.0003
86-99 (n=977) 0.57 0.44 - 0.75 0.0001
72-85 (n=1015) 0.61 0.47-0.79 0.0002
< 72 (n=900) 0.69 0.52- 0.92 0.002
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BB, 31% were due to failure to restart BB following hospitalization. More vigilance regard-
ing restoration of BB usage following hospital discharge is in order.
POSTER SESSION
1108 Heart Failure: Outcomes II
Monday, March 08, 2004, 3:00 p.m.-5:00 p.m.
Morial Convention Center, Hall G
Presentation Hour: 4:00 p.m.-5:00 p.m.
1108-109 Low Hemoglobin Is an Independent Predictor of 
Adverse Fatal and Nonfatal Outcomes in Both Reduced 
and Preserved Systolic Function Chronic Heart Failure: 
Findings From the Candesartan in Heart Failure 
Assessment of Reduction in Mortality and Morbidity 
Program (CHARM)
John J. McMurray, Chim C. Lang, Karl Swedberg, Jan Östergren, Christopher B. 
Granger, Eric Michelson, James B. Young, Bertil Olofsson, Mark Dunlap, Salim Yusuf, 
Marc A. Pfeffer, for the CHARM Investigators, Western Infirmary, Glasgow, United 
Kingdom
Background: Low hemoglobin (Hb) is associated with higher mortality in patients with
chronic heart failure (CHF) and a reduced left ventricular ejection fraction (LVEF).
Whether Hb is an independent predictor of survival and also predicts non-fatal outcomes
is unclear. The importance of Hb in CHF and preserved LVEF is unknown.
Methods: The 3 CHARM trials were: i) CHARM-Alternative (n= 2028): LVEF < 0.40 intol-
erant of an ACE inhibitor (ACE-I) ii) CHARM-Added (n=2548): LVEF < 0.40 taking an
ACE-I iii) CHARM-Preserved (n=3025): LVEF > 0.40. Patients were randomised to pla-
cebo or candesartan and followed for 37.7 months. Outcomes were compared in those
with Hb < and > median (13.6g/dL).
Results: Unadjusted outcomes are shown in the table. In a multivariate analysis Hb was
an independent predictor of outcomes in both reduced LVEF and preserved LVEF CHF.
For the 2 low LVEF trials combined, the hazard ratios (HR) for > median versus < median
Hb were: Death 0.62 95% CI (0.51-0.75) p<0.0001; CHF hospitalization 0.72 (0.60-0.86)
p=0.0005 and death or CHF hospitalization 0.68 (0.58-0.78) p<0.0001. For CHARM-Pre-
served the HR were: 0.63 (0.46-0.86) p=0.004, 0.62 (0.47-0.81) p=0.0005 and 0.65
(0.52-0.81) p=0.0002, respectively.
Outcome in overall CHARM Programme according to whether baseline haemoglo-
bin was above or equal to/below median 
Conclusion: Hb is an independent predictor not only of death but also of CHF hospital-
ization. Hb is of as much prognostic significance in CHF with preserved LVEF as in CHF 
with a reduced LVEF.
1108-110 Pulmonary Edema Prognostic Score: A Novel Simple 
Prognostic Tool for Short-Term Events in Acute 
Cardiogenic Pulmonary Edema
Marcin Fiutowski, Tomasz Waszyrowski, Maria Krzeminska-Pakula, Jaroslaw D. 
Kasprzak, Medical University of Lodz, Lodz, Poland, Jonscher Hospital, Lodz, Poland
BACKGROUND: Cardiogenic pulmonary edema (CPE) is a common reason of hospitali-
sation connected with high mortality, but few data are published regarding long- and
short-term prognosis and no prognostic scales are in use.
AIM: To establish a simple score predicting the in-hospital prognosis in patients with
CPE.
METHODS AND RESULTS: We studied 276 Pts (148 females; mean age 70 years) hos-
pitalised due to CPO (hospital stay 12±7 days). In-hospital mortality was 21%. 44 clinical
variables were included in the analysis to revealthe most significant mortality predictors:
acute myocardial infarction (RR=2,12), heart rate:>115/min. (RR=2,13), systolic blood
pressure < 130mmHg (RR=3,61) and white blood cells>11500/mm3 (RR=2,26) on pre-
sentation. The number of risk factors was summed to create pulmonary edema prognos-
tic score (PEPS). PEPS had a linear relationship with mortality - figure. Pts with PEPS 0
had very good short-term prognosis with 2% in-hospital mortality rate (RR=0,07)
whereas mortality in Pts with PEPS 4 was 64% (RR=3,31). Receiver operating character-
istic curve analysis proved good discriminative ability (AUC= 0,78). Score above 1 had
sensitivity of 79%, specificity of 62%, 36% positive and 92% negative predictive value for
in-hospital mortality
CONCLUSIONS: Pulmonary edema prognostic score is a simple bedside tool allowing a
precise prediction of in-hospital prognosis after acute cardiogenic pulmonary edema.
1108-111 Serum Hyaluronic Acid Elevation in Patients With 
Decompensated Congestive Heart Failure Is 
Independent of Left Ventricular Systolic Function
Leonardo C. Clavijo, Daniel J. Cantillon, Jinguo Chen, Lurong Zhang, Michael D. 
Greenberg, Cynthia M. Tracy, Georgetown University, Washington, DC
BACKGROUND: Hyaluronic acid (HA), an extracellular glycosaminoglycan, is elevated
during hepatic hypoperfusion, edema and fibroproliferative disorders. Serum HA is 90%
metabolized and excreted by the liver. We have recently demonstrated that serum HA is
elevated in patients (pts) with decompensated CHF (dCHF).
HYPOTHESIS: Serum HA elevation in pts with clinically dCHF is independent of LV sys-
tolic function (LVSF) and CHF etiology (ischemic vs. non-ischemic), thus reflecting poor
hepatic perfusion and edema.
METHODS: A novel enzyme linked immunosorbent assay (ELISA) was used to measure
serum HA levels in two hundred pts consecutively admitted to the hospital. Fourteen pts
were excluded due to chronic liver disease or renal insufficiency. All dCHF pts were
symptomatic and the diagnosis confirmed by a cardiologist blinded to HA level. Based on
LVSF measured by echocardiogram, gated nuclear imaging or ventriculogram dCHF pts
were divided in two groups: dCHF + preserved LVSF (EF>40%) or dCHF + depressed
LVSF (EF <40%). Ischemic cardiomyopathy was identified by the presence or absence of
coronary disease in the setting of dCHF.
RESULTS: Admission serum HA levels were markedly elevated in pts with dCHF (259.0
ng/ml, SEM=49.5, n=32) vs. non-CHF pts (104.0 ng/ml, SEM=6.2, n=154), p<0.001.
Serum HA levels in pts with dCHF + preserved LVSF (348.5 ng/ml, SEM=106.2, n=14)
and dCHF + depressed LVF (189.4 ng/ml, SEM=24.4, n=18) were elevated compare to
non-CHF pts (104.0 ng/ml, SEM=6.2, n=154), p<0.001. The difference between dCHF
with preserved and depressed LVSF was not significant (p=0.11). There was no differ-
ence in HA levels between ischemic and non-ischemic dCHF groups (293.3 ng/ml,
SEM=71.9, n=21 vs. 193.3 ng/ml, SEM=41.3, n=11), p=0.27.
CONCLUSION: Serum hyaluronic acid level is elevated in pts with symptomatic clinically
dCHF. HA elevation is independent of left ventricular systolic function and ischemic etiol-
ogy. Further studies are needed to investigate the mechanisms and prognostic value of
HA elevation during dCHF.
1108-112 An Embolic Event to Death in More Than 50 Percent of 
Patients With Idiopathic Dilated Cardiomyopathy in End- 
Stage Heart Failure
Antonio C. Barretto, Sr., Mucio T. Oliveira Jr, Sr., Robinson T. Munhoz, Sr., Airton R. 
Scipioni, Sr., Maria L. Higuchi, Jose A F Ramires, Sr., Heart Institute, (InCor), University 
of São Paulo Medical School, São Paulo, Brazil
Background: Pts with idiopathic dilated cardiomyopathy (IDC) and end stage heart failure
has a worse prognosis with high mortality. Embolic events (EE) could contribute to the
heart failure bad evolution of these pts.
Objective: To clarify the importance of EE in the evolution of pts with IDC, we analyzed
the data from necropsies of heart failure pts that died at the hospital in the last ten years.
Methods: Between 1990 and 1999, 3847 necropsies were performed and 118 pts had
IDC. The pts mean age was 41.8 years and 74 (62,7%) were male. The echocardiogram
showed a mean LV end diastolic diameter of 76,0 mm and a mean LV ejection fraction of
0,32. Results: EE were identified in 90 (76,3%) pts, 61 (51,7%) of those had pulmonary
embolism (PE), 29 (24,6%) systemic embolism (SE) and 33 (14.2%) both. The great
majority of EE was not diagnosis in life. Cardiac thrombus was detected in right cham-
bers in 26 pts (22,0%) and in left chambers in 18 (24,62%). The main embolic source
Hb > median
(n=1368)
Hb <
median
(n=1281)
Outcome (%)
death 19.0 27.9
CHF hospitalization 22.5 30.3
Death or CHF hospitalization 33.5 44.9
